Genmab As Stock Operating Margin
| GNMSF Stock | USD 196.00 0.36 0.18% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab A/S's financial success or failures. It also enables traders to predict the movement of Genmab Pink Sheet. The fundamental analysis module provides a way to measure Genmab A/S's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab A/S pink sheet.
Genmab |
Genmab AS Company Operating Margin Analysis
Genmab A/S's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Genmab A/S Operating Margin | 0.38 % |
Most of Genmab A/S's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Genmab AS has an Operating Margin of 0.3755%. This is 101.07% lower than that of the Healthcare sector and 100.34% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 106.81% lower than that of the firm.
Genmab Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genmab A/S's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genmab A/S could also be used in its relative valuation, which is a method of valuing Genmab A/S by comparing valuation metrics of similar companies.Genmab AS is currently under evaluation in operating margin category among its peers.
Genmab Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.47 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 26.41 B | |||
| Shares Outstanding | 65.96 M | |||
| Shares Owned By Institutions | 49.90 % | |||
| Price To Earning | 39.08 X | |||
| Price To Book | 7.94 X | |||
| Price To Sales | 2.45 X | |||
| Revenue | 8.48 B | |||
| Gross Profit | 8.48 B | |||
| EBITDA | 4.24 B | |||
| Net Income | 3.01 B | |||
| Cash And Equivalents | 21.61 B | |||
| Cash Per Share | 330.53 X | |||
| Total Debt | 634 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 13.11 X | |||
| Book Value Per Share | 408.67 X | |||
| Cash Flow From Operations | 2.23 B | |||
| Earnings Per Share | 12.00 X | |||
| Price To Earnings To Growth | 1.20 X | |||
| Target Price | 383.57 | |||
| Number Of Employees | 1.56 K | |||
| Beta | 0.67 | |||
| Market Capitalization | 26.78 B | |||
| Total Asset | 24.63 B | |||
| Retained Earnings | (3.96 B) | |||
| Working Capital | 3.72 B | |||
| Current Asset | 4.14 B | |||
| Current Liabilities | 419 M | |||
| Z Score | 25.2 | |||
| Net Asset | 24.63 B |
About Genmab A/S Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab A/S using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Stocks Directory module to find actively traded stocks across global markets.